Literature DB >> 15286208

Specific inhibition of nuclear factor-kappaB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer.

William A Sands1, Anthony F Martin, Elaine W Strong, Timothy M Palmer.   

Abstract

Adenosine is a potent inhibitor of inflammatory processes, and the A(2A) adenosine receptor (A(2A)AR) plays a key nonredundant role as a suppresser of inflammatory responses in vivo. In this study, we demonstrate that increasing A(2A)AR gene expression suppressed multiple inflammatory responses in both human umbilical vein endothelial cells (HUVECs) and rat C6 glioma cells in vitro. In particular, the induction of the adhesion molecule E-selectin by either tumor necrosis factor alpha (TNFalpha) or Escherichia coli lipopolysaccharide (LPS) was reduced by more than 70% in HUVECs, whereas inducible nitric-oxide synthase (iNOS) induction was abolished in C6 cells after exposure to interferon-gamma in combination with LPS and TNFalpha, suggesting that the receptor inhibited a common step in the induction of each of these pro-inflammatory genes. Consistent with this hypothesis, A(2A)AR expression inhibited the activation of NF-kappaB, a key transcription factor whose proper function was essential for optimal iNOS and E-selectin induction. However, although NF-kappaB binding to target DNA was severely compromised in both cell types, the mechanisms by which this occurred were distinct. In C6 cells, A(2A)AR expression blocked IkappaBalpha degradation by inhibiting stimulus-induced phosphorylation, whereas in HUVECs, A(2A)AR expression inhibited NF-kappaB translocation to the nucleus independently of any effect on IkappaBalpha degradation. Together, these observations suggest that A(2A)AR-mediated inhibition NF-kappaB activation is a critical aspect of its anti-inflammatory signaling properties and that the molecular basis of this inhibition varies in a cell type-specific manner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286208     DOI: 10.1124/mol.104.001107

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

Review 2.  Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction.

Authors:  T M Palmer; M A Trevethick
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

3.  High glucose-treated macrophages augment E-selectin expression in endothelial cells.

Authors:  Te-Chuan Chen; Shao-Ju Chien; Hsing-Chun Kuo; Wen-Shih Huang; Jiunn-Ming Sheen; Tseng-Hsi Lin; Chia-Kuang Yen; Mao-Lin Sung; Cheng-Nan Chen
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

4.  Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells.

Authors:  William A Sands; Hayley D Woolson; Gillian R Milne; Claire Rutherford; Timothy M Palmer
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  Adenosine A(2A) agonist and A(2B) antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation.

Authors:  Sebastian Michael; Claudia Warstat; Fabien Michel; Luo Yan; Christa E Müller; Karen Nieber
Journal:  Purinergic Signal       Date:  2009-12-18       Impact factor: 3.765

6.  Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice.

Authors:  Ana Flávia Torquato de Araújo Junqueira; Adriana Abalen Martins Dias; Mariana Lima Vale; Graziela Machado Gruner Turco Spilborghs; Aline Siqueira Bossa; Bruno Bezerra Lima; Alex Fiorini Carvalho; Richard Littleton Guerrant; Ronaldo Albuquerque Ribeiro; Gerly Anne Brito
Journal:  Infect Immun       Date:  2010-11-29       Impact factor: 3.441

7.  Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson.

Authors:  Joshua J Field; Gene Lin; Maureen M Okam; Elaine Majerus; Jeffrey Keefer; Onyinye Onyekwere; Ainsley Ross; Federico Campigotto; Donna Neuberg; Joel Linden; David G Nathan
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

8.  Macrophage A2A adenosinergic receptor modulates oxygen-induced augmentation of murine lung injury.

Authors:  Neil R Aggarwal; Franco R D'Alessio; Yoshiki Eto; Eric Chau; Claudia Avalos; Adam T Waickman; Brian T Garibaldi; Jason R Mock; Daniel C Files; Venkataramana Sidhaye; Vsevolod Y Polotsky; Jonathan Powell; Maureen Horton; Landon S King
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

9.  Effects of adenosine A2a receptor agonist and antagonist on hippocampal nuclear factor-kB expression preceded by MDMA toxicity.

Authors:  Fatemeh Kermanian; Mansooreh Soleimani; Alireza Ebrahimzadeh; Hossein Haghir; Mehdi Mehdizadeh
Journal:  Metab Brain Dis       Date:  2012-12-06       Impact factor: 3.584

Review 10.  Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions.

Authors:  M A Trevethick; S J Mantell; E F Stuart; A Barnard; K N Wright; M Yeadon
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.